Navigation Links
Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical,Trial in Second Quarter

MELBOURNE, Australia, May 03, 2007 /PRNewswire-FirstCall/ -- Phosphagenics Limited (AIM: PSG) announced today that the Company intends to initiate a Phase 1b clinical trial to demonstrate the efficacy and safety of the improved formulation of its transdermal insulin product, TPM-02/Insulin, containing long-acting insulin. The trial is expected to commence in the second quarter of 2007.

TPM-02/Insulin gel is being developed as a novel "needle-free" way of administering insulin to patients with diabetes. Following the successful completion of a Phase 1a study utilizing short-acting insulin, this trial will assess an optimized formulation of long-acting insulin. Recent advancements in Phosphagenics' patented TPM-02 delivery system have enabled the formulation of long-acting insulin; which is significantly less expensive than short- acting insulin, provides appropriate levels of insulin in humans and is commercially attractive.

"In August of 2006, our Phase 1a study demonstrated that a single application of TPM-02/Insulin gel rapidly delivered insulin across the skin and into the bloodstream without any adverse reactions," said Dr. Esra Ogru, Executive Vice President at Phosphagenics. "Additionally, it significantly lowered blood glucose, insulin and c-peptide levels."

"The Phase 1b study is intended to provide additional supporting data for an Investigational New Drug application to the U.S. Food and Drug Administration," continued Dr. Ogru. "The trial will be conducted by CMAX at the Royal Adelaide Hospital, South Australia, will include up to 45 healthy volunteers and is expected to lead directly into the start of a large multi- site Phase 2 trial that is likely to include up to several hundred patients."

"This is an important step for the development and commercialization of TPM-02/Insulin," said Harry Rosen, President and CEO of Phosphagenics. "This technology has the potential to p
'"/>




Page: 1 2

Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/23/2014)... ANGELES , July 23, 2014  Researchers from ... with calcium elevates calcium levels too high, ... among other health problems. Women close to ... and vitamin D to prevent diseases such as osteoporosis, ... would recommend that women determine how much calcium they ...
(Date:7/23/2014)... BOSTON , July 23, 2014  The ... CBRX ) will hold a conference call ... for the second quarter ended June 30, 2014. ... July 31, 2014Time: , 8:30 am EDTDial-in numbers: ... (Canada) or,International: (412) 317-0790Webcast (live & archive): , ...
(Date:7/23/2014)... , July 23, 2014  Cardica, Inc. (Nasdaq: ... for its fiscal fourth quarter and year ended June 30, ... Cardica,s management will host a conference call at 4:30 p.m. ... update on the company,s business. Conference Call Details ... at 4:30 p.m. Eastern Time via phone, please dial 866-953-6859 ...
Breaking Medicine Technology:Women Taking Too Much Calcium Create Health Risk 2Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2
... Evergreen Hospital – one of the region,s leaders in ... gallbladder removal in the Washington and Oregon region on ... a procedure just approved by the FDA. ... two patients – a 66-year-old man and a 33-year-old ...
... March of Dimes announced today that Watson Pharmaceuticals has become ... the March of Dimes number one fundraising event, and will ... the organizations will also work to raise awareness of risk ... participating in March for Babies events around the country as ...
Cached Medicine Technology:Evergreen Hospital to Perform Region's First Single-Incision Gallbladder Removal 2Evergreen Hospital to Perform Region's First Single-Incision Gallbladder Removal 3Watson Partners With March of Dimes to Help Fight Preterm Birth 2
(Date:7/23/2014)... By using brightly hued dyes, George Mason University ... proteins touch each other, possibly leading to new ... lung disease. , George Mason researchers unraveled the ... touch each other. "One protein interlocks with another ... and this sends a signal down the line ...
(Date:7/23/2014)... Boston, MA (PRWEB) July 23, 2014 ... software technologies, the leasing and financing company LeaseQ ... in the server based software sector, they still ... sectors. , To learn more about technology ... Tirey, Founder and CEO of LeaseQ was quoted ...
(Date:7/23/2014)... 23, 2014 Splashtop , ... announce that it has joined the RSA Ready ... Splashtop Enterprise and RSA SecurID® multi-factor authentication solution ... , Splashtop also announced that leading ... deploying Splashtop Enterprise, the industry‚Äôs only on-premise remote ...
(Date:7/23/2014)... joined together for the first time to call for ... people worldwide suffering from the condition. , Psoriatic arthritis ... joint damage if left untreated. , PsA tends to ... a red, scaly rash, and affects approximately two per ... one in five go on to develop PsA ...
(Date:7/23/2014)... 2014 On July 21, 2014, My Positive ... Jack Tracey for an episode that spoke about the group ... asks Tracey to talk some about the formation of the ... mission, it was started right here in Charleston, originally it ... to help survivors of sexual abuse. Their purpose has shifted ...
Breaking Medicine News(10 mins):Health News:Researchers unlock the protein puzzle 2Health News:LeaseQ Announces That Although Software Investment Remains Sluggish, Technology Equipment Leasing Demand Remains Robust 2Health News:LeaseQ Announces That Although Software Investment Remains Sluggish, Technology Equipment Leasing Demand Remains Robust 3Health News:Splashtop Joins RSA® Ready Technology Partner Program; Announces Adoption by Leading Japan Insurance Group Nissei Asset Management 2Health News:Splashtop Joins RSA® Ready Technology Partner Program; Announces Adoption by Leading Japan Insurance Group Nissei Asset Management 3Health News:Psoriatic arthritis patients need better screening, warns panel of experts 2Health News:My Positive Perspective Airs Episode to Raise Attention to the Group Darkness to Light 2
... By Randy Dotinga HealthDay Reporter , THURSDAY, ... more evidence that people infected with HIV, the virus that ... as other patients when they undergo kidney transplants. Up ... to HIV patients because of fear that AIDS would quickly ...
... hosting an event on World Aids Day, bringing together some ... future projections for the AIDS pandemic., The panel speakers are ... of Hygiene & Tropical Medicine and former Executive Director of ... Larson, Director of aids2031, an independent consortium set up by ...
... HealthDay Reporter , THURSDAY, Nov. 18 (HealthDay News) ... procedure, can be made more precise by combining a ... Researchers found that a femtosecond laser, used for many ... tissue more cleanly and accurately than manual cataract surgery, ...
... Reporter , WEDNESDAY, Nov. 17 (HealthDay News) -- Using the ... that doctors, prescribing patterns vary across the country in response ... Administration. The result is that patients may be ... live, the researchers said. "We were looking at the ...
... a cardiomyopathy about which little is fully understood, is ... according to a study to be presented Nov. 17 ... in Chicago. The researchers also will report that advanced ... to progress over time in patients with LVNC. ...
... international, multi-center study has revealed the discovery of a novel ... form of eye cancer. Researchers have isolated an oncogene called ... than 40 percent of tumor samples taken from patients with ... November 17, 2010 in the New England Journal of ...
Cached Medicine News:Health News:HIV Patients Do Well After Kidney Transplants: Study 2Health News:HIV Patients Do Well After Kidney Transplants: Study 3Health News:AIDS: Taking a long-term view 2Health News:Study Reports More Precise Way to Remove Cataracts 2Health News:Study Reports More Precise Way to Remove Cataracts 3Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 2Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 3Health News:Cardiac MR sheds light on obscure heart muscle condition 2Health News:Novel genetic mutation that causes the most common form of eye cancer discovered 2
... Freedom leg bags are part ... a versatile line of leg bags, ... the varied needs of our customers. ... several sizes, and constructed of 100% ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
... Freedom leg bags are part of ... versatile line of leg bags, kits, ... varied needs of our customers. These ... sizes, and constructed of 100% latex-free ...
... Rochester Medical's line of ... intermittent catheters you would ... four product configurations - ... antibacterial hydro - are ...
Medicine Products: